{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:47:35Z","timestamp":1762660055197,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>The coronavirus disease 2019 (COVID-19) pandemic has had unprecedented impact on the provision of medical care for genetic disorders. The purpose of this study was to assess the effects of the pandemic on neurofibromatosis (NF) care and research.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Sixty-three United States NF clinics were surveyed to identify the impact of the pandemic on clinician role, patient volume, continuity of guideline-driven surveillance, research protocols, and use of (and satisfaction with) telehealth for the delivery of NF care.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifty-two clinic directors or their representatives completed the survey (83% response rate). About 2\/3 of the clinics reported a greater than 50% decrease in the number of available patient appointments, and modified clinical surveillance and research protocols. Fifty-one clinics (98%) newly instituted telehealth during the pandemic. Barriers to telehealth prior to the pandemic were insurance reimbursement concerns and lack of infrastructure. Since telehealth was initiated, high provider satisfaction was reported with ease of use. The most common area of concern was related to inability to perform a physical examination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Results show marked impacts on NF care and research since the beginning of the pandemic, with potential long-term changes related to the introduction (or adoption) of telehealth for clinical care.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13023-021-01711-w","type":"journal-article","created":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T12:04:22Z","timestamp":1612181062000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The impact of the COVID-19 pandemic on neurofibromatosis clinical care and research"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1557-7390","authenticated-orcid":false,"given":"Heather B.","family":"Radtke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonita P.","family":"Klein-Tasman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa L.","family":"Merker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Knight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole J.","family":"Ullrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin T.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Korf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott R.","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"key":"1711_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1023\/B:NEON.0000041891.39474.cb","volume":"69","author":"AK Bhattacharyya","year":"2004","unstructured":"Bhattacharyya AK, Perrin R, Guha A. Peripheral nerve tumors: management strategies and molecular insights. J Neurooncol. 2004;69:335\u201349. https:\/\/doi.org\/10.1023\/B:NEON.0000041891.39474.cb.","journal-title":"J Neurooncol"},{"key":"1711_CR2","unstructured":"World Wide Web: U.S. Food & Drug Administration, 2020. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-selumetinib-neurofibromatosis-type-1-symptomatic-inoperable-plexiform-neurofibromas. Accessed Sept 2020."},{"key":"1711_CR3","unstructured":"World Wide Web: NIH U.S. National Library of Medicine, 2020. https:\/\/clinicaltrials.gov\/. Accessed Sept 2020."},{"issue":"1","key":"1711_CR4","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1186\/s12913-018-3471-5","volume":"18","author":"VL Merker","year":"2018","unstructured":"Merker VL, Dai A, Radtke HB, Knight P, Jordan JT, Plotkin SR. Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis. BMC Health Serv Res. 2018;18(1):668. https:\/\/doi.org\/10.1186\/s12913-018-3471-5.","journal-title":"BMC Health Serv Res."},{"key":"1711_CR5","unstructured":"World Wide Web, Children\u2019s Tumor Foundation, 2020. https:\/\/www.ctf.org\/doctor. Accessed Sept 2020."},{"key":"1711_CR6","unstructured":"World Wide Web, Centers for Disease Control and Prevention, 2020. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/faq.html#Basics. Accessed Sept 2020."},{"key":"1711_CR7","unstructured":"World Wide Web, Centers for Disease Control and Prevention, 2020. https:\/\/cdc.gov\/mmwr\/volumes\/69\/wr\/mm6918e2.htm. Accessed Sept 2020."},{"issue":"5","key":"1711_CR8","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.dsx.2020.06.042","volume":"14","author":"YV Chudasama","year":"2020","unstructured":"Chudasama YV, Gillies CL, Zaccardi F, et al. Impact of COVID-19 on routine care for chronic diseases: a global survey of views from healthcare professionals. Diabetes Metab Syndr. 2020;14(5):965\u20137. https:\/\/doi.org\/10.1016\/j.dsx.2020.06.042.","journal-title":"Diabetes Metab Syndr"},{"key":"1711_CR9","unstructured":"World Wide Web, The University of Alabama at Birmingham, Neurofibromatosis Consortium, 2020. https:\/\/www.uab.edu\/nfconsortium\/sites. Accessed Sept 2020."},{"key":"1711_CR10","doi-asserted-by":"crossref","unstructured":"Wolters PL, Reda S, Martin S, Al Ghriwati N, Baker M, Berg D, Erickson G, Franklin B, Gates M, Merker V, Oberlander B, Reeve S, R\u00f6hl C, Rosser T, Tamula MA, Vranceanu AM. Impact of the Coronavirus Pandemic on Mental Health and Healthcare in Adults with Neurofibromatosis: Results from an Anonymous Psychosocial Survey. Oral Presentation at the Virtual European NF Conference, Rotterdam, Netherlands, Dec 2020.","DOI":"10.1002\/ajmg.a.62490"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01711-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-021-01711-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01711-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T05:44:01Z","timestamp":1670996641000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01711-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1711"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01711-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"type":"electronic","value":"1750-1172"}],"subject":[],"published":{"date-parts":[[2021,2,1]]},"assertion":[{"value":"2 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HBR, PK, BPKT report no competing interests and the remaining authors report no competing interests related to this work. VLM is independent contractor for the Neurofibromatosis Network; JTJ receives consulting income from CereXis and Recursion pharmaceuticals, Navio Theragnostics, and Health2047, Inc. Royalties from Elsevier; BK is on the medical advisory board for Genome Medical, scientific advisory board for SpringWorks and has received support from AstraZeneca; and advisory board for Infixion; NJU was a one-time consultation lecturer for Astra Zeneca; SRP is a co-founder of NFlection therapeutics and NF2 Therapeutics; consultant for AstraZeneca and SonalaSense.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}